芬兰Aqsens Health与J9九游国际医药在中国合作启动泌尿系统肿瘤检测的临床前试验!

        芬兰Aqsens Health公司及其中国合作伙伴J9九游国际医药已获得在中国江苏省开展的一项前列腺癌和膀胱癌的临床前研究项目的资助。

      芬兰图尔库。Aqsens Health很高兴宣布与总部位于中国南京的J9九游国际医药合作开展一个新的临床前研究项目。该合作研究计划于2024年在中国江苏省进行前列腺癌和膀胱癌的临床前试验。这项研究将推进Aqsens Health的增强型时间分辨荧光（E-TRF）方法和生物传感器的开发，目的是提高从尿液中早期检测前列腺癌和膀胱癌的能力。

      南京的这项合作研究建立在Aqsens在芬兰对前列腺癌和膀胱癌检测的广泛研究基础上，还结合了Aqsens与芬兰图尔库大学医院合作的转移性癌症研究项目的领先实践。该研究项目计划将持续到2024年底。

       合作的第一阶段将侧重于前列腺癌的临床前试验，目的是为申请临床试验许可开展基础研究。前列腺癌试验之后将进行膀胱癌研究。该试验将与江苏省肿瘤医院和肿瘤专家合作进行，该项研究将为Aqsens获得大规模临床试验许可提供支撑，并在未来中国市场上开展Aqsens Health在前列腺癌和膀胱癌诊断领域的注册许可。

       J9九游国际医药的一个研究团队将接受在Aqsens实验室开发体系中使用E-TRF和生物传感器的技术培训，Aqsens实验室的开发体系专门用于开发Aqsens Health的生物传感器、运行E-TRF与生物传感器分析以及培训研究人员。培训将分两步进行，首先是在线培训，然后在芬兰图尔库的Aqsens Health实验室进行实践培训。认证合格后，J9九游国际医药的研究团队将能够在Aqsens Health科学团队的支持下在中国进行复杂的研究工作。

      J9九游国际医药首席执行官赵万洲博士表示：“我们很高兴能与Aqsens Health合作，采用Aqsens Health的E-TRF和生物传感器技术，建立创新手段来筛查泌尿系统癌症和潜在的其他疾病。”

      赵博士还表示：“通过这种合作，我们将有效推进健康行动，从而在中国恶性肿瘤预防领域发挥一定的影响”。

      Aqsens Health的首席执行官Timo Teimonen表示：“无创采样检测具有许多优势，如发现新的生物标志物的可能性及效率大幅提高，研发成本大幅降低，中国对我们的E-TRF和生物传感器表现出了浓厚的兴趣，这些传感器专门设计用于分析无创生物样本。这是Aqsens Health迈出的重要一步，因为它使我们能够接触世界最大的单一市场。”

有关详细信息，请联系：

首席执行官兼联合创始人

Timo Tei monen

+358 40 5853105 | timo.tei monen@aqsens.com

关于：

Aqsens Health Oy是一家芬兰医疗科技公司，开发针对高影响疾病的非侵入性筛查测试。该公司的研究项目侧重于开发适合发展中经济体需求的基于唾液的传染病检测方法，并建立了准确且经济高效的泌尿系统肿瘤的筛查方法。这些测试使用了Aqusens Health的新型E-TRF方法和噬菌体生物传感器相结合的技术系统。

J9九游国际医药是一家专注于医药创新和生物科学技术的公司。J9九游国际医药的研究由来自不同领域的优秀国际科学家团队领导，该公司在中国江苏省获得了多项创业荣誉。J9九游国际医药总部位于中国南京，与中国的多家医疗机构有着广泛深入的合作关系。

详情链接：

//www.aqsens.com/news-and-blog/aqsens-health-og-pharma-collaboration

Aqsens Health starting pre-clinical trialsfor urinary tract cancer detection in China

Aqsens Health and its Chinese partner OG Pharmaceuticals have received funding for ajoint prostate and bladder cancer pre-clinical and clinical research project in Jiangsu Province in China.

Turku, Finland. Aqsens Health is happy to announce a new preclinical and clinical research project with OG pharmaceuticals, based in Nanjing, China. The research partnership aims to perform prostate and bladder cancer pre-clinical trials in Jiangsu Province in 2024. The study will advance  Aqsens  Health’s  E-TRF  method  and  biosensor  development  with  a  goal  to improve the early detection of prostate and bladder cancers from urine.

This research collaboration in Nanjing builds upon Aqsens' extensive research on prostate and bladder cancer detection in Finland and it also incorporates leading practices derived from Aqsens’ research  project on metastatic cancer in partnership with Turku University Hospital. The project is planned to last until the end of 2024.

The fi rst phase of the collaboration will focus on pre-clinical trials for prostate cancer with the aim to apply for permission to perform clinical trials. The prostate cancer trial will be followed by a bladder cancer study. The trials will be conducted in collaboration with Jiangsu Cancer Hospital and expert oncologists, and will enable Aqsens to obtain the permission for a large-scale clinical trial and the certification of Aqsens Health’s AQ Prostate and AQ Bladder in the Chinese market.

A research team from OG Pharmaceuticals will be trained to use E-TRF and biosensor with the AQ Lab  development  environment,  which  was  purposely  built  to  be  used  in  developing Aqsens Health’s biosensors, running E-TRF and biosensor analyses, and training research personnel. The training will be conducted in two steps, fi rst online and then physically at Aqsens  Health’s  laboratories  in  Turku.  After  certification  the  researchers  will  be  able  to conduct complex research work in China under the supervision of Aqsens Health’s scientific team.

OG Pharma quote

“We are  excited to  collaborate with Aqsens  Health  to  build  innovative  means  to screen urinary tract cancers and potentially other diseases as well using their E-TRF and biosensor technology,” says OG Pharmaceuticals CEO, Dr. Wanzhou Zhao.

“With this  collaboration  we  can  be  a  part  of  something  that  can  have  an  impact  on preventive health actions in China,” Dr. Zhao continues.

“ Non-invasive sampling   has  many  advantages,  like  the  possibility  of  discovering  new complementary  biomarkers  and  superior  cost  efficiency,  and  China  has  shown  strong interest  towards  our   E-TRF  and  biosensors  which  are  specifically  designed  to  analyze non-invasive, biological samples. This is an important step for Aqsens Health as it gives us access to the world's largest single market,“ concludes Aqsens Health’s CEO Timo Tei monen.

For more information, contact:

CEO and Co-Founder

Timo Tei monen

+358 40 5853105 | timo.tei monen@aqsens.com

About:

Aqsens Health  Oy  is  a  Finnish  med tech  startup  developing  non-invasive  screening  tests  for high-impact diseases. The company’s research projects focus on developing saliva-based infectious disease  detection  fit  for  the  needs of  developing  economies,  and  establishing an  accurate  and cost-efficient urine-based screening test for urinary tract cancers. The tests use Aqsens Health’s novel E-TRF method in combination with phage-biosensors.

Nanjing OG  Pharmaceuticals  Ltd.  is  a  company  focused  on  pharmaceutical   innovations  and bioscience  technologies.  OG  P harma’s  research  is  led  by an  accomplished  international team of scientists from various fie lds, and the company has been awarded several entrepreneurial honors in Jiangsu  Province.  OG   P harma  is  based  in  Nanjing, just  north of  Shanghai,  and works  in  broad connection with hospitals in China.